{"id":"W4396587723","doi":"10.1158/1538-7445.sabcs23-po2-18-09","title":"Abstract PO2-18-09: A phase 3 randomized open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy in patients with ER+/HER2– early breast cancer and an intermediate or high risk of recurrence (CAMBRIA 1)","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Cancer; Breast cancer; Endocrine system; Adjuvant; Oncology; Adjuvant therapy; Internal medicine; Open label; Randomized controlled trial; Hormone","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001471882,0.0004573359,0.001676194,0.000522684,0.0001001652,0.0001097422,0.0004803338,0.00006640526,0.0004468613],"category_scores_gemma":[0.00005902321,0.0002577927,0.0000496354,0.001063743,0.0009812282,0.0005950265,0.0001088534,0.0009163528,7.545378e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003688586,"about_ca_system_score_gemma":0.001789949,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03129042,"about_ca_topic_score_gemma":0.005464524,"domain_scores_codex":[0.9956688,0.0005873807,0.0007900054,0.0009419945,0.00130507,0.0007066949],"domain_scores_gemma":[0.9970832,0.000463589,0.0003125631,0.00069271,0.001147125,0.0003007695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6138086,0.003678932,0.03356496,0.0002075405,0.0009486159,0.000127446,0.003845779,0.00001505959,0.001265172,0.00001365087,0.000009526526,0.3425147],"study_design_scores_gemma":[0.6088233,0.02257173,0.3613147,0.002867576,0.0001271362,0.00001614807,0.001011965,0.00007300365,0.00266584,0.0001200571,0.00007318307,0.0003353404],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863188,0.005053802,0.00002734518,0.0002490781,0.0001368965,0.006708572,0.001448033,0.00003974664,0.00001767279],"genre_scores_gemma":[0.9800153,0.01767182,0.0002110068,0.00002458729,0.0001079527,0.001753956,0.00002740433,0.0001156645,0.00007229832],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3421793,"threshold_uncertainty_score":0.9999874,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05914551455094619,"score_gpt":0.438484531426877,"score_spread":0.3793390168759308,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}